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Abstract
Nucleic acid aptamers are small oligonucleotides that specifically bind to other molecules
through noncovalent interactions that rely on complex tridimensional structural arrange‐
ments. Aptamers are generated through the iterative in vitro selection method called SE‐
LEX, resulting in specific binding against a wide variety of molecular targets including
viruses. Because aptamers are obtained in vitro and can be synthetically produced, they
have been envisioned as future diagnostic and therapeutic tools for human diseases in‐
cluding virus-borne pathologies. Aptamers have been isolated against a number of virus‐
es including pandemic influenza virus, human papillomavirus and hepatitis C virus.
Although aptamers have proven themselves as extremely sensitive detection tools trig‐
gering the development of affordable and highly diagnostic methods, their use as thera‐
peutic moieties has been hampered by biostability, delivery and pharmacodynamical
issues. Nevertheless, a new generation of chemically modified aptamers shows promise
for the coming of age of protein-targeted noncatalytic oligonucleotides for the therapy of
viral disease. The present review focuses on the most successful antiviral aptamers re‐
ported and includes a description of some of the novel methods developed for their use
as diagnostic and therapeutic tools
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1. Introduction
Nucleic acid aptamers are small single-stranded oligonucleotides capable of adopting complex
tertiary structures that allow noncovalent interactions with other molecules. Because aptamers
closely interact with their targets, their structural features are essential for highly specific
binding. The term aptamer was coined in 1990 from the Latin “aptus” meaning “fitting” and
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the Greek “meros” meaning “particle” [1]. Aptamers are generated through the iterative in
vitro selection method called SELEX (systematic evolution of ligands by exponential enrich‐
ment) and are raised against a wide variety of molecular targets ranging from ions and
macromolecules to whole organisms, including viruses, bacteria, yeast and mammalian cells
[2]. Although many modifications to the SELEX method have been established to include new
technologies and improve selection [3], the basic steps of SELEX remain immutable.
The SELEX method involves three well-defined steps [4]: the start point is the production of a
synthetic oligonucleotide combinatorial library or oligonucleotide pool containing a central
randomized region (15–70 nt) flanked by anchor sequences to allow polymerase chain reaction
(PCR) amplification. The aleatory nature of the central region results in the production of an
enormous pool of diverse oligonucleotides with diverse structures, thus providing the
conformational variability necessary to produce moieties with binding capabilities for a
desired target. The oligonucleotide pool can be directly used for SELEX to generate single-
stranded DNA (ssDNA) aptamers, or as in vitro transcription template to produce an RNA
pool to isolate RNA aptamers. Next, a selection procedure is performed based on the interac‐
tion properties of the library with the intended target. Only a very small fraction of the
oligonucleotide pool tends to interact with the target, satisfying the selection criteria. Oligo‐
nucleotides that bind the target (aptamers) are recovered while the nonbound are removed
through different strategies according to the nature of the aptamer–ligand complex (size,
affinity, electric charge, hydrophobicity, etc.). In the final step, the recovered aptamers are
amplified by PCR in order to regenerate a library with less variability but more affinity to the
target that will be used in the next selection cycle. RNA pools are amplified by reverse
transcription-coupled PCR (RT-PCR) and subsequent in vitro transcription before starting the
next cycle.
The iterative selection cycles produce aptamers with high binding affinity to the target.
Usually, a few cycles are required to isolate aptamers (4–20 cycles), but the precise number of
cycles necessary for the isolation of highly specific aptamers depends on the selection criteria,
the nature of the target and the type of library used. After the last selection cycle, aptamers are
cloned and sequenced to obtain information on the individual oligonucleotides, which can be
further characterized based on its ability to bind the target. It is common to observe conserved
sequences or structures among the selected aptamers; these are indicative of efficient selection
and may represent domains required for interaction.
Aptamer specificity is based on three-dimensional arrangements of a small number of contact
points between the aptamer and its target, so the aptamer can achieve high selectivity to
discriminate between two highly related molecules (i.e. enantiomers), or minimal structural
differences such as the presence or absence of methyl or hydroxyl groups. The molecular
recognition specificity and affinity level achieved by aptamers is comparable or even better
than those of antibodies. These features place aptamers as an emerging class of molecules on
their own with a huge range of diagnostic and therapeutic applications plus several advantages
over antibodies including:
• Isolation by an in vitro process not dependent on animal cells or in vivo conditions. Therefore,
the properties of aptamers can change on demand, and isolation can be manipulated to
Nucleic Acids - From Basic Aspects to Laboratory Tools94
obtain aptamers with desirable properties for diagnosis. In addition, it allows aptamer
isolation against toxins or poorly immunogenic molecules.
• Production by chemical synthesis with accuracy and reproducibility, thus insuring mass
production with high quality control standards.
• Aptamers can be reversibly denatured allowing conditional binding through simple
temperature control.
Since the development of SELEX, aptamers have been isolated against a wide diversity of
targets such as amino acids [5, 6], antibiotics [7], nucleotides [8], enzymes [9], growth factors
[10], mammalian cells [11], bacteria [12] and parasites [13]. Nowadays, some aptamers have
even reached therapeutic applications in the clinic [14]. Furthermore, the first RNA aptamer
for therapeutic purposes in humans (pegaptanib sodium or Macugen®) was approved by
United States Food and Drug Administration (FDA) in 2004, as treatment for age-related
macular degeneration (AMD) [15].
2. Aptamers against viruses
Many aptamers have been isolated against whole viruses or viral proteins to detect or inhibit
infection. Viruses such as human papillomavirus (HPV), human immunodeficiency virus-1
(HIV-1), hepatitis C virus (HCV), hepatitis B virus (HBV), severe acute respiratory syndrome
coronavirus (SCoV), influenza virus, herpes simplex virus (HSV), Ebola virus, Rift Valley fever
virus, dengue virus, human T cell leukemia virus type-1 (HTLV-1), Epstein–Barr virus and
human cytomegalovirus (HCMV) have all been targeted with aptamers [16].
Aptamer isolation to inhibit viral infection can be performed by using purified molecules from
the viral surface through canonical SELEX approaches, or by modified SELEX methods with
the use of attenuated whole viral particles. The advantage of this last variant is the isolation
of aptamers through binding to the native viral conformation. Moreover, a deep knowledge
of the viral infection mechanisms or potential surface target molecules is not required to obtain
antiviral or neutralizing aptamers that tightly bind infectious particles. On the other hand, this
method does not disclose the sites that directly interact with the aptamers, so further studies
are required to determine specific interactions useful for potential aptamer improvement.
Many efforts have been focused on the isolation of aptamers to detect and treat viral diseases
relevant to public health such as AIDS, hepatitis, influenza and some cancers. Here, we
summarize the successful application of aptamers selected against HIV-1, HPV, HCV, and
influenza.
2.1. Aptamers against Rous Sarcoma Virus (RSV)
The first approach using whole viruses to isolate RNA aptamers without previous knowledge
of the virion structural features was performed against Rous sarcoma virus (RSV), an avian
retrovirus. Nineteen RNA aptamers were isolated from a canonical SELEX procedure and five
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of them were able to neutralize the virus infection [17]. These results immediately revealed the
potential of aptamers isolated against viral surface epitopes leading to the development of
nucleic acid aptamers as novel diagnostic or therapeutic tools, especially on human viral
diseases requiring fast diagnostics (i.e. pandemic influenza or Ebola) or asymptomatic chronic
viral-induced conditions such as acquired immunodeficiency syndrome (AIDS), hepatitis C
or cervical cancer [18].
2.2. Aptamers against Human Immunodeficiency Virus type I (HIV-1)
HIV-1 is the etiologic agent of AIDS [19, 20]. Most anti-HIV-1 aptamers are directed to HIV-1
reverse transcriptase (RT), RNaseH, integrase, Tat, Gag, nucleocapsid, gp120 and the TAR-
element RNA (Table 1). The HIV-1 RT is the enzyme responsible for transforming the viral
genomic RNA into dsDNA and contains a domain with RNaseH activity. HIV-1 RT is also the
main target of several therapies against AIDS. So far, about a dozen of ssDNA and RNA
aptamers have been reported to inhibit the RT activity in cell cultures showing KD in the range
of 25 pM to 30 nM [18, 21].
Aptamer Nature Sequence Randomized
region
Target Action Structure Ref
P5 RNA
GGGAGCUCAGAAUAAACG
CUCAACGGCACAGGGGUU
GUAUCCUCCGGGACGAAU
UCGACAUGAGGCCCGGAU
CCGGC
30 nt Integrase
Inhibit interaction
between integrase and
viral DNA
Allen P, et al.
1995
A54 RNA
GGGAGCUCAGAAUAAACG
CUCAAGUCAAUCAUCGAU
GUCCUGUGCCCUAGGGCU
UCGACAUGAGGCCCGGAU
CCGGC
30 nt Integrase
Inhibit interaction
between integrase and
viral DNA
Allen P, et al.
1995
93del DNA GGGGTGGGAGGAGGGT 80 nt Integrase Block integrase actvityin vitro
Phan AT, et
al. 2004, De
Soultrait VR.
Et. al. 2002
112del DNA CGGGTGGGTGGGTGGT 80 nt Integrase Inhibton of HV-1integrase
, De Soultrait
VR. Et. al.
2002
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Aptamer Nature Sequence Randomized
region
Target Action Structure Ref
RNA tat RNA
ACGAAGCUUGAUCCCGUU
UGCCGGUCGAUCGCUUCG
A
120 nt TAR
Inhibition of Tat
dependent trasns-
activation
transcription.
Biosensor
Yamamoto R,
et al. 2000
B40 RNA
TAATACGACTCACTATAGG
GAGACAAGACTAGACGCT
CAaTGTGGGCCACGCCCGA
TTTTACGCTTTTACCCGCAC
GCGATTGGTTTGTTTTCGA
CATGGACTCACAACAGTTC
CCTTTAGTGAGGGTTAATT
40 nt Gp120 Neutralizaton ofHIV-1 infectivity
Khati M, et al.
2003.
Dey AK, et al.
2005.
B40t77 RNA
TAATACGACTCACTATAGG
GAGACAAGACTAGACGCT
CAATGTGGCCACGCCCGAT
TTTACGCTTTTACCGCACG
CGATTGGTTTGTTTCCC
40 nt Gp120 Neutralizaton ofHIV-1 infectivity
Dey AK, et al.
2005. Cohen
C, et al, 2008.
Table 1. Aptamers isolated against HIV proteins.
The HIV-1 integrase incorporates the viral DNA in the host genome [22]. RNA aptamers were
isolated targeting HIV-1 integrase and classified into three groups according to their KD (10
nM, 80 nM and 800 nM) [23]. Furthermore, DNA aptamers were also isolated targeting HIV-1
integrase by two different research groups, all with G-quadruplex structures and showing in
vitro inhibitory activity [24, 25]. The characteristic structure of aptamers binding the HIV-1
integrase interacts within a channel of the tetrameric protein blocking catalytic amino acid
residues essential for integrase function in vitro [26].
HIV-1 Tat protein regulates viral gene expression by interaction with the trans-activation
responsive (TAR) elements within the long-terminal repeats (LTRs) [27]. Unlike the natural
target of Tat (TAR-1 RNA), the isolated RNA aptamer (RNATat) was highly specific to Tat and
did not interact with other cellular factors. Moreover, RNATat binds Tat protein over 100-fold
higher than TAR-1 RNA and inhibited Tat function in vitro and in vivo [28, 29]. Based on these
results, RNATat was used in a preliminary study to develop a molecular beacon by flanking
the 5′ and 3′ ends of the native aptamer stem-loop structure with a fluorophore and a quencher.
In the absence of Tat, the quencher and fluorophore remain close to each other by the formation
of the stem producing no signal. When the loop interacts with Tat, the complexed structure
becomes more stable resulting in strand separation, thus holding apart the fluorophore and
quencher allowing fluorescence [30].
Two other biosensors have been developed using RNA aptamers specific to HIV-1 Tat. These
biosensors were created by immobilizing a biotinylated aptamer on a streptavidin layer over
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quartz crystals included in surface plasmon resonance (SPR) chips [31]. Another approach
used a diamond field-effect transistor (FET) technique to detect Tat protein by RNA aptamers.
Aptamer-FET is based on a gate potential shift generated by the presence of HIV-1 Tat bound
to the RNA aptamer on a solid diamond surface. Efficient detection showed a potential use for
aptamer-FET in clinical applications [32].
HIV-1 Rev is essential to regulate the splicing and shuttle the viral mRNA through their nuclear
and export localization signals. Also, Rev interacts with viral mRNA through a cis-acting Rev-
binding element (RBE) within a Rev-responsive element (RRE). RNA aptamers against Rev
have been isolated using random libraries or by randomizing the RRE minimal binding
sequence [33–35]. Randomized RRE produced aptamers with up to 16-fold tighter binding
than the minimal wild-type RBE (wtRBE). The RBE was then substituted by these RNA
aptamers and tested in vivo using a reporter system [35]. The aptamer substitutions showed a
better response than wtRBE [36]. Another technique used to isolate RNA aptamers against Rev
protein was the cross-linking SELEX consisting of a 5′-iodo uracil (5-IU)–modified RNA
library, which is reactive under long-wavelength UV irradiation producing cross-links
between 5-IU oligonucleotides and the protein target. This method resulted in the selection of
highly specific aptamers capable of forming covalent bonds with HIV-1 Rev [37]. Some other
efforts have focused on the inhibition of HIV-1 replication in human T cells using RNA
aptamers as decoys to sequester Rev [38]. Rev decoys and ribozymes have been combined to
increase the anti-HIV effect relative to independent ribozyme or decoy effects [39–41].
HIV-1 gp120 is a surface glycoprotein involved in the early stages of HIV-1 infection. The gp120
protein interacts with the human surface receptor CD4 producing conformational changes and
further receptor interactions to allow HIV-1 entry into the host cell. Due to its importance on
the onset of the viral infection, gp120 represents a potential target for the isolation of aptamers
to block HIV-1 entry. Several RNA aptamers have been isolated to block gp120 and CD4
interaction neutralizing diverse subtypes of the virus [42]. Characterization of aptamer B40
showed high specificity to HIV-1 R5 strain and neutralization in human peripheral blood
mononuclear cells [43, 44]. Additional analyses produced a shorter synthetic B40 derivative
(UCLA1) able to inhibit entry of HIV-1 at the nanomolar range. Moreover, the aptamer showed
synergistic effects with a gp41 fusion inhibitor (T20) and anti-CD4 binding site monoclonal
antibody (IgG1b12), suggesting a potential use as adjuvant [45].
2′-Fluoride (2′-F) modified RNA aptamers selected to bind HIV-1Bal gp120 and specifically
internalized by cells expressing HIV-1Bal gp120 were used to deliver anti-HIV siRNA into
HIV-1–infected cells [46]. Two aptamer-siRNA chimeras were used: one covalent chimera
presented a 2′-F-modified gp120 aptamer covalently attached to the sense strand of tat/rev
siRNA and reduced the plasma viral load in a RAG-hu mouse model by suppressing HIV-1
replication and preventing CD4+ T cell decline. This effect was extended by several weeks
beyond the last dose [47]. The second chimera consisted of a single aptamer with three different
siRNAs targeting viral and cellular transcripts. The siRNA was linked to the aptamer by a
bridge sequence of 16 nt that allowed complementary base pairing of one of the two siRNA
strands to the aptamer. The aptamer–siRNA chimera showed a potent suppression of HIV-1
and protection from viral CD4+ T-cell depletion in vivo. In addition, the inhibitory effects were
Nucleic Acids - From Basic Aspects to Laboratory Tools98
also extended several weeks after the last injection, providing an attractive therapeutic
approach to HIV-1 therapy [48].
2.2.1. Aptamers against HPV
HPVs are small DNA viruses that infect squamous epithelia inducing proliferative lesions
ranging from benign warts to cancer. High-grade papillomavirus, especially types 16 and 18
(HPV-16 and HPV-18) are associated with cervical carcinoma, the second most common cancer
affecting women worldwide. HPVs have a circular double-stranded DNA genome of approx‐
imately 8 kb that is organized into three regions: the upstream regulatory region (URR), the
early region (E) and the late region (L). The URR contains several transcription factor binding
sites to control gene expression, the early region encodes six genes (E1, E2, E4, E5, E6 and E7)
involved in viral replication, transcription and cell transformation and the late region encodes
the L1 and L2 capsid proteins which self-assemble to produce the virion [49].
Because preventive vaccines for HPV infection are only protective for naive individuals [50],
several research groups have been developing nucleic acid–based aptamers targeting HPV
proteins in order to inhibit the oncoproteins activity, block viral infection or identify the
absence/presence of viral proteins as biomarkers to determine cell transformation or cancer
progression (Table 2).
Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
F2 RNA GGGAAUGGAUCCA
CAUACUACGAAUA
UUCAACAUUCGAG
GUGGAUGCUACGA
AUCAACUUCACUG
CAGACUUGACGAA
GCUU
30 nt E6 Inhbition of E6-PDZ
(Magil1) interaction and
Induction of apoptosis in
SiHa cells
ND Belyaeva
TA, et al.
2014
F4 RNA GGGAAUGGAUCCA
CAUACUACGAAAA
CUCGUUUCGAGGU
UCGAAACGUUGUA
AAGCCGUUUCACU
GCAGACUUGACGA
AGCUU
30 nt E6 Inhbition of E6-PDZ
(Magil1) interaction and
Induction of apoptosis in
SiHa cells
ND Belyaeva
TA, et al.
2014
A2 RNA GGGAAUGGAUCCA
CAUCUACGAAUCC
CUUCAUCAUUAAC
CCGUCCACGCGCU
UCACUGCAGACUU
GACGAAGCUU
30 nt E7 Inhibition of E7-pRb
interaction and Induction of
apoptosis in SiHA cells
Nicol C. et
al, 2013
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
G5a3N.4 RNA GGGAGACCCAAGC
CGAUUUAUUUUGU
GCAGCUUUUGUUC
CCUUUAGUGAGGG
UUAAUU
15 nt E7 E7 high affinity binding on
HPV-positive cervical
carcinoma cells
Toscano-
Garibay JD,
et al. 2011
Sc5-c3 RNA GGGAACAAAAGCU
GCACAGGUUACCC
CCGCUUGGGUCUC
CCUAUAGUGAGUC
GUAUUA
15 nt L1 High affinity binding of
HPV VLPs in murire
biofluids
Leija-
Montoya
AG, et al.
2014
C5 RNA GGGAGGACGAUGC
GGAAGCATCAAGG
GTGATCGTTTGACC
CTCCCCAGACGAC
UCGCCCGA
30 nt HPV-16
E6/E7-
HTECs
Internalization in HPV-16
E6/E7 HTEC as mechanism
to deliver therapeutc agents
Gourronc
FA, et al.
2013
13 DNA ATACCAGCTTATTC
AATTGGGCACAGA
CGGAAGATGAGAA
TTGTGGGGCTTAGT
ATAGTGAGGTGCGT
GTAGATAGTAAGTG
CAATCT
52 nt HF cell line Detection of biomarkers lost
in HPV-mediated cell
transformation
Graham JC,
et al. 2012
14 DNA ATACCAGCTTATTC
AATTGGGCGGGGA
GTAGGGAGAGGGG
TTTCCATCGGCGAC
AGAGGAGTTATGTG
TGTAGATAGTAAGT
GCAATCT
52 nt HF cell line Detection of biomarkers lost
in HPV-mediated cell
transformation
Graham JC,
et al. 2012
20 DNA ATACCAGCTTATTC
AATTGGGGAGGGA
GACACAGTCATGG
AGCAGTTATTAGGG
TGTACCGGGTGTAG
TAGATAGTAAGTGC
AATCT
52 nt HF cell line Detection of biomarkers lost
in HPV-mediated cell
transformation
Graham JC,
et al. 2012
28 DNA ATACCAGCTTATTC
AATTGGGGGACAC
GGAGGTGGTGGAA
52 nt HF cell line Detection of biomarkers lost
in HPV-mediated cell
transformation
Graham JC,
et al. 2012
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
AGGCTAAGATTTGA
TGATGAGTAGTGTG
GTAGATAGTAAGTG
CAATCT
Table 2. Aptamers isolated against HPV proteins.
The oncoproteins E6 and E7 are involved in cell immortalization and malignant transforma‐
tion. E6 promotes the degradation of the tumor suppressor p53 [51], and E7 binds and
destabilizes the cell cycle control protein pRb [52]. E6 and E7 have an important role in cancer
progression, situating these oncoproteins as the principal potential targets to bind aptamers
to block their oncogenic activity and cancer progression.
Several RNA aptamers were isolated against the PDZ-binding motif of the HPV-16 E6
oncoprotein, two of them were able to inhibit the interaction between E6 and proteins with
PDZ domain (Magi 1) resulting in apoptosis. The aptamer interaction with PDZ domain was
very specific and the interaction between E6 and p53 was not affected [53]. The same research
group also isolated RNA aptamers against E7 oncoprotein that were able to disturb the E7–
pRb interaction by targeting E7 for degradation and showed that one of them (A2) was able
to inhibit cellular proliferation by inducing apoptosis in SiHa cervical carcinoma cells [54]. This
effect was specific to HPV-16 transformed cells because it was not observed in HPV-free or
HPV-18 cell lines [55]. Specific apoptosis induction of RNA aptamers targeting E6 and E7
oncoproteins suggests that these aptamers could have further applications in the future as
therapeutic moieties.
A deeply characterized RNA aptamer targeting HPV-16 E7 oncoprotein named G5α3N.4
interacts with E7 through two stem-loop motifs in a clamp-like manner, suggesting a change
in aptamer structure due to protein contact. The complex formation was observed exclusively
in HPV-positive cervical carcinoma cells, suggesting that G5α3N.4 could be used to detect
HPV infection and cervical cancer [56, 57].
The L1 protein is the main component of the HPV capsid. It is arranged in 72 capsomers, each
consisting of five 55-kDa L1 monomers and a single 74-kDa L2 unit (theoretical 5:1 ratio). The
L1 protein can self-assemble, forming virus-like particles (VLPs) that are structurally and
immunologically similar to the infectious virions. HPV-16 L1 VLPs have been broadly used in
HPV virology research, as delivery agents for epitopes or genes and to successfully produce
prophylactic vaccines against HPV infection. The first RNA aptamer, targeting the L1 protein
(Sc5-c3), was obtained using HPV-16 VLPs as targets [58]. Sc5-c3 structure consists of a hairpin
structure with a 16-nt loop that directly binds VLPs with very low KD (0.05 pM). This aptamer
was able to specifically bind VLPs in complex protein mixtures (murine cervical washes),
suggesting that Sc5-c3 may provide a potential diagnostic tool for active HPV infections and,
with further refinement, could be used as a potential tool to inhibit viral infection [58].
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Nucleic acid–based aptamers have been also isolated against whole HPV-infected cells. A cell-
based SELEX protocol (cell-SELEX), was used to isolate RNA aptamers able to internalize into
HPV-16 E6/E7 transformed human tonsillar epithelial cells (HTEC). This was the first report
of aptamers that specifically internalize into HPV-16–transformed cells, providing a plausible
mechanism to specifically deliver therapeutic agents into HPV-16–associated tumors [59].
Moreover, DNA aptamers have been isolated by a cell-SELEX modification for use with
adherent cells (AC-SELEX). These aptamers recognize cell surface differences between HPV-
transformed and nontumorigenic cell lines and one of them (Aptamer 14) was able to enter
the cells independent of cell surface protein binding. These selected aptamers have potential
to elucidate biomarkers for cellular changes associated to nontumorigenic phenotype in HPV-
infected cells [60].
2.3. Aptamers against influenza virus
Influenza viruses are associated with most flu pandemics. They are enveloped RNA viruses
of 80 to 120 nm diameter that infect the upper respiratory tract. The disease severity depends
on the virus type: A, B or C. Influenza A virus infects birds and mammals, influenza B targets
mainly humans and influenza C is less common than A or B but it also causes disease. Although
the three virus types infect different hosts, it has been reported that all of them can infect
humans and thus they have been the subject of several SELEX protocols.
2.3.1. Influenza A Virus (IAV)
The IAV genome comprises eight segments of linear RNA and two surface glycoproteins:
hemagglutinin (HA) and neuraminidase (NA). These proteins are used to classify the IAV
subtypes. Seventeen HA (H1–H17) and nine NA (N1–N9) variants have been identified and
implicated on viral attachment, membrane fusion and viral entry to the host cell. Many
aptamers have been isolated to bind HA and NA in order to inhibit and detect the viral
infection, mainly H5N1, H9N2, H1N1 and H3N2 subtypes (Table 3).
Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
H3N2
A22 DNA AATTAACCCTCACTAA
AGGGCTGAGTCTCAAA
ACCGCAATACACTGGT
TGTATGGTCGAATAAG
TTAA
30 nt HA
(91-161)
Inhibition of viral
infection
Jeon SH, et
al. 2004
A21 DNA AATTAACCCTCACTAA
AGGGCGCTTATTTGTTC
AGGTTGGGTCTTCCTAT
TATGGTCGAATAAGTT
AA
30 nt HA
(91-161)
Inhibition of viral
infection
Jeon SH, et
al. 2000
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
P-30-10-1
6
RNA GGGAGAAUUCCGACC
AGAAGGGUUAGCAGU
CGGCAUGCGGUACAG
ACAGACCUUUCCUCU
CUCCUUCCUCUUCU
30 nt A/Panama/
2007/1999
Inhibition of viral
infection.
Discriminate
between related
H3N2
Gopinath
SC, et al.
2006
H5N1
10 DNA GATTCAGTCGGACAGC
GGGGTTCCCATGCGGA
TGTTATAAAGCAGTCG
CTTATAAGGGATGGAC
GAATATCGTCTCCC
40 nt HA In vitro Inhibition
of viral infection
Cheng C, et
al.2008
2 DNA GTGTGCATGGATAGCA
CGTAACGGTGTAGTAG
ATACGTGCGGGTAGGA
AGAAAGGGAAATAGTT
GTCCTGTTG
74 nt HA and whole
H5N1
H5N1 detection
(QCM aptasensor)
Wang
R,and Li Y.
2013
H9N2
A9 DNA GCTGCAATACTCATGG
ACAGCCTCCTGGGGTC
AGGCTCAGACATTGAT
AAAGCGACATCGGTCT
GGAGTACGACCCTGAA
40 nt HA Inhibition of viral
infection
YueweiZha
ng, et al.
2015
B4 DNA GCTGCAATACTCATGG
ACAGGGGCCGCGCCTG
GTCGGTTGGGTGGGTG
GCGCCCGGGACGGTCT
GGAGTACGACCCTGAA
40 nt HA Inhibition of viral
infection
YueweiZha
ng, et al
2015
H5N1 AND H7N7
8-3S RNA GGGCAACCGCUGGAA
CUUGAAGUCGGUAAU
GCGAGCGGAAAGCCC
70 nt HA Discriminate IVA
subtypes,
inhibition of
receptor binding
Suenaga E
and Kumar
PK, 2014.
H5N1, HIN1 AND H3N2
RHA000
6
DNA GGGTTTGGGTTGGGTT
GGGTTTTTGGGTTTGGG
TTGGGTTGGGAAAAA
30 nt rHA IVA detection
(ELAA)
Shiratori I,
et al. 2014
RHA038
5
DNA TTGGGGTTATTTTGGGA
GGGCGGGGGTT
30 nt rHA IVA detection
(ELAA)
Shiratori I,
et al. 2014
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
RHA163
5
DNA GGGGCCCACCCTCTCG
CTGGCGGCTCTGTTCTG
TTCTCGTCTCCTTGATT
TCTGTGGGCCCC
30 nt rHA IVA detection
(ELAA)
Shiratori I,
et al. 2014
Table 3. Aptamers against human IAV proteins.
Two DNA aptamers, A21 and A22, were isolated against an HA peptide containing amino
acid positions 91–261. A22 was the most efficient aptamer to inhibit viral infection in vivo and
in vitro by blocking the cellular receptor from binding HA. Moreover, A22 showed high
binding activity against different IAV strains (H3N2 and H2N2) and reduced virus burden by
90%–99% in mice [61]. Further studies using the whole virus demonstrated the ability of RNA
aptamers to distinguish between related strains within the H3N2 subtype of influenza type A
viruses [62]. The selected aptamer P30-10-16 was able to discriminate between A/Panama/
2007/1999 and A/Aichi/2/1968 H3N2 subtypes and its binding affinity to HA was even 15-fold
higher compared with a monoclonal antibody specific to HA. A consensus aptamer sequence
(5′-GUCGNCNU(N)23GUA-3′) was selected by surface plasmon resonance (SPR) using an
RNA pool based on randomized P30-10-16 (doped RNA pool). The GNCNU sequence was
identified as the minimal element required to bind HA [63], suggesting a potential use as tools
for influenza virus genotyping.
An aptamer selected against H5N1 HA (A10), showed inhibition of receptor binding produc‐
ing in vitro inhibition of viral infection [64]. To increase the specificity, some aptamers were
isolated using recombinant HA in the initial selection cycles and then the whole inactivated
H5N1 virus for further selection cycles. The selected aptamers were able to discriminate among
H5N2, H5N3, H5N9, H9N2 and H7N2, showing better specificity than anti-H5N1 monoclonal
antibodies [65]. These aptamers were used on quartz crystal microbalance (QCM) biosensors
coated with hydrogel. The hydrogel consisted of cross-linked hybridized ssDNA and aptamer.
In the presence of H5N1 the hybridization is disturbed producing hydrogel swelling which is
detected by a QCM sensor [66].
Although some aptamers have been isolated to bind a specific IVA subtype, some others
identify more than one virus subtype. A 113-nt-long RNA aptamer (8-3) was isolated against
HAs from H5-N1 and H7N7. The full 8-3 and shortened version called 8-3S aptamer were able
to bind HA with high affinity and interfere with the cell surface HA–glycan interaction,
suggesting a potential application in diagnosis and interference of virus–host interactions [67].
Furthermore, DNA aptamers were selected against recombinant hemagglutinin (rHa) to detect
different subtypes of IVA such as H5N1, H1N1 and H3N2. The selected DNA aptamers:
RHA0006, RH0385 and RHA1635 were able to successfully bind the three mentioned IVA
subtypes. RHA0006 and RH0385 were also used in a sandwich enzyme-linked aptamer assay
(ELAA), developing a novel, rapid and cost-effective diagnostic tool to identify various IVA
subtypes [68].
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2.3.2. Influenza B Virus (IVB)
Some aptamers have been isolated against whole virus or purified proteins in order to
discriminate IVB from IVA (Table 4). An RNA aptamer against HA B/Johannesburg/05/1999
virus was able to discriminate between the HA from different strains and prevented viral
infection by membrane fusion inhibition [62]. Two aptamers have been selected against intact
HA of influenza strains B/Tokyo/S3/99 and Jilin/20/2003. The sensitivity of Tokyo aptamer was
approximately 250-fold higher than a commercial antibody, demonstrating its potential to
detect influenza viruses [69].
Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
Class A-20 RNA GGGAGCUCAGCCUUCAC
UGCACUCCGGCUGGUGG
ACGCGGUACGAGCAAUU
UGUACCGGAUGGAUGU
UCGGGCAGCGGUGUGGC
AGGGAUGAGCGGCACCA
CGGUCGGAUCCAC
74 nt HA Discriminate
between stran A
and B. Membrane
fusion inhibition
Gopinath
JC, et al.
2006
Tokio virus
aptamer
(clone D)
RNA GGGAGAAUUCCGACCAG
AAGUUUUUGUUUAUAU
UGUUGUUUUAUUCCUU
UCCUCUCCUUCCUCUUC
U
25 nt Whole virus
(Tokio virus)
Dscriminaton of
influenza viruses
and detection
Lakshmipri
ya T, et al.
2013
Jilin-HA
aptamer
RNA GGGAGAAUUCCGACCAG
AAGGGUCUACGCCCGAA
GGGUUGCCGUGCCUUUC
CUCUCUCCUUCCUCUUC
U
25 nt HA (Jilin HA) Dscriminaton of
influenza viruses
and detection
Lakshmipri
ya T, et al.
2013
Table 4. Aptamers against IBV.
2.4. Aptamers against HCV
HCV is one of the causes of chronic liver disease associated with end-stage cirrhosis and
hepatocellular carcinoma. HCV are small enveloped viruses with a linear single-stranded RNA
+ genome containing a single ORF encoding a polyprotein flanked by untranslated regions
(UTR) and processed into three structural proteins (C, E1 and E2) and seven nonstructural
proteins (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B). The 5′-UTR contains an internal
ribosomal entry site (IRES) important for mediated translation by association with the host cell
small ribosomal unit (40S). Due to its importance in viral infection, replication and prolifera‐
tion, HCV aptamers have been mainly isolated against NS3, NS5 proteins and some IRES
domains (Table 5).
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
10-G1 RNA GGGAACUCGAUGAAGCGA
AUUCUGUUGGCGAACUGU
ACGCAAGUACACUGGAUG
ACAGCCUAUCUAUCUAUC
GGAUCCACG
10-18 nt NS3 Inhibition of in vitro
activity
Urvil PT, et al.
1997
G6-16 RNA GGGAGAAUUCCGACCAGA
AGGCUUGCUGUUGUUUCC
CUGUUGUUUUGUCUCUCA
ACUUUAUUGUGGUAAAGA
UCACUGGGUUGAUAAGGG
CUAACUCUAAUUUGACUA
CAUGGUCGGACCAAUCAG
UUCUUAUGGGAGAUGCAU
AUGUGCGUCUACAUGGAU
CCUCA
120 nt NS3 Inhibition of
proteolytic activity
Kumar PK, et
al. 1997
G6-19 RNA GGGAGAAUUCCGACCAGA
AGCUCUUAUACUAUUAAC
GCUACCGUGUCAUUGUAC
UUGGUAGUGUUGAUGGUU
UGGGUCGCAUUUGGCUUG
GCUUAUGGUUUUUUCACC
CUACCUCUCAUUGACGCA
GUAGGCUCUCAUAUGUGC
GUCUACAUGGAUCCUCA
120 nt NS3 Inhibition of
proteolytic activity
Kumar PK, et
al. 1997
G9-I RNA GGGAGAAUUCCGACCAGA
AGCUUCGGGAUUUGAGGG
UAGAAUGGGACUACCUUU
CCUCUCUCCUUCCUCUUC
U
30 nt ∆NS3 Inhibition of
proteolytic activity
Fukuda K, et
al. 2000
G9-II RNA GGGAGAAUUCCGACCAGA
AGUGCUCUUAGAAUGGGA
CUAAGACACGGGACCCUU
UCCUCUCUCCUUCCUCUU
CU
30 nt ∆NS3 Inhibition of
proteolytic activity
Fukuda K, et
al. 2000
G9-III RNA GGGAGAAUUCCGACCAGA
AGUACGACACGAUUGGGA
CGUGUCUAUGGGACCCUU
UCCUCUCUCCUUCCUCUU
CU
30 nt ∆NS3 Inhibition of
proteolytic activity
Fukuda K, et
al. 2000
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Aptamer Nature Sequence Randomized
region
Target Function Structure Ref
B-2 RNA GGGAUGCUUCGGCAUCCC
CGAAGCCGCUAUGGACCA
GUGGCGCGGCUUCGGCCC
GACGGAGUGGUACCGCUU
CGGCGGUACGUAAGCUUG
GG
25 nt - 10 nt NS5B Inhibition of RNA
polimerase activity in
vitro
Biroccio A, et
al. 2000
r10/43 DNA GGGAGACAAGAATAAACG
CTCAAGGGCGTGGTGGGTG
GGGTACTAATAATGTGCGT
TTGTTCGACAGGAGGCTCA
CAACAGGC
36 nt NS5B Inhibition of specific
subtype 3a
polymerase activity
Jones LA, et
al. 2006
r10/47 DNA GGGAGACAAGAATAAACG
CTCAATTGGGGTCTGCTCG
GGATTGCGGAGAACGTGA
ATCTTTCGACAGGAGGCTC
ACAACAGGC
36 nt NS5B Inhibition of specific
subtype 3a
polymerase activity
Jones LA, et
al. 2006
NS2-2 DNA CAGGTACCACCTTCATGGG
CGCGGAAGACGATGGTGTA
CTA
40 nt NS2 Distrup Ns2 - Ns5b
interaction. Inhibition
of NS2 activity
ND Gao Y, et al.
2014
NS2-3 DNA ACGGGGCAGGATTGTCCCC
GCGCCTGGTTGAAGGTAGT
CGC
40 nt NS2 Inhibithion of NS2
activity
ND Gao Y, et al.
2014
ZE2 DNA GCGGAATTCTAATACGACT
CACTATAGGGAACAGTCCG
AGCCGAATGAGGAATAATC
TAGCTCCTTCGCTGAGGGT
CAATGCGTCATAGGATCCC
GC
30 nt E2 Competitive
inhibithion of E2 -
CD81 binding . Block
HCV infection.
Chen F, et al.
2009
E1E2-6 DNA ACGCTCGGATGCCACTACA
G(N40)CTCATGGACGTGCTG
GTGAC
40 nt E1E2 Inhibition of aptamer
binding to the host cell
ND Yang D, et al.
2013
Table 5. Aptamers isolated against HCV proteins.
NS3 has a trypsin-like serine protease and NTPase/helicase activity [70, 71]. NS3 is required
for proteolytic processing of nonstructural proteins [72]. The HCV protease domain disrupts
the interferon (IFN) and toll-like receptor-3 (TLR3) signaling pathways by cleaving the caspase
recruitment domain of mitochondrial antiviral signaling protein (MAVS) and the TIR domain
containing an adapter-inducing interferon-β sequence (TRIF) [73]. As NS3 activity is crucial
for viral replication, many aptamers have been isolated against NS3.
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The 10G-1 RNA aptamer was selected against NS3 protease domain using a 12–18 nt random‐
ized library and can reduce protease activity by 20% compared with serine protease inhibitors
[74]. However, a new SELEX protocol was used to select anti-NS3 aptamers with improved
binding and inhibition activities increasing the structural pool complexity by using larger
randomized domains (120 nt) and competition against 10G-1. As a result, two new RNA
aptamers were selected (G6–16 and G6–19) showing efficient NS3 binding. The G6–16
concentration needed to inhibit 50% of the NS3 activity was 3 µM, and although both aptamers
inhibited the protease and helicase activity, they showed lower efficacy compared with known
serine protease inhibitors [75]. To further improve aptamer efficacy and inhibit the NS3 RNA
binding helicase, a truncated form (∆NS3) only including the protease domain was used as a
target, and the random sequence of the RNA pool was reduced to 30 nt to ease the SELEX
process. Three highly specific aptamers (G9-I, G9-II and G9-III) were obtained against ∆NS3
containing the conserved sequence GA(A/U)UGGGAC that was present inside an identical
loop in all aptamer structures. These aptamers showed KD values of 11.6 nM, 6.3 nM and 8.9
nm, respectively. The G9 aptamers produced 90% of NS3 protease activity inhibition alone
and 70% in the presence of NS4A used to simulate physiological conditions [76]. Structure
analyses suggested that interaction of stem I and stem-loop II is essential to G9-I aptamer NS3
binding. To achieve in vivo applications, the G9-II aptamer was conjugated with cis-acting
genomic human hepatitis delta virus (HDV) ribozymes. The aptamer was inserted into the
nonfunctional stem IV region of the HDV ribozyme promoting in vivo stable structure that
lasted up to 4 days after transfection. The HDV ribozyme–G9-II aptamer (HA) was attached
to nuclear export signal CTEM45 (HAC) and ligated in tandem to increase the aptamers dosage
in cells. These new constructs showed efficient NS3 protease inhibition in vivo and in vitro [77].
To also inhibit NS3 helicase activity, a poly U tail (14U) was added to the minimum functional
sequence of the G9-I aptamer (∆NEOIII) to mask and inhibit the helicase substrate-binding
region [78]. NEOIII-14U displayed dual functions by inhibiting NS3 protease activity in vivo
and in vitro and inhibiting the NS3 unwinding helicase reaction (IC50 1 µM) [79].
More RNA aptamers were selected against NS3 helicase domain, including the conserved
sequence GGA(U/C)GGAGCC at stem-loop regions. Further deletion and mutagenesis
analyses demonstrated that the whole structure of the conserved stem-loop is needed for
helicase inhibition. Aptamer #5 presented the best inhibition of helicase in vitro activity with
an IC50 of 50 nM [77]. Bifunctional aptamers constructed conjugating RNA aptamers ∆NEOIII
and G9-II with aptamer #5 through an oligo U spacer. The spacer length was optimized by
protease and helicase inhibition assays [80]. The resulting advanced dual-functional (ADD)
aptamers (NEO-34-s41 and G925-s50) showed superior inhibitory activities of NS3 [81].
NS5B is an RNA-dependent RNA polymerase that synthesizes the HCV-negative strand RNA
using genomic positive RNA strand as a template. NS5B has an essential role in the HCV’s life
cycle and its variability has been associated with worse disease prognosis [82]. The highly
specific B.2 RNA aptamer selected against a truncated NS5B target (NS5B∆C55) presented a
conserved sequence that was folded on stem loop structure associated with a tight interaction
to NS5B (KD = 1.5 ± 0.2 nM). Also, B.2 demonstrated inhibition of NS5B activity by a noncom‐
petitive mechanism [9].
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Two DNA aptamers selected against NS5B (27v and 127v) showed inhibition of polymerase
activity in vitro. Although both aptamers were isolated from the same SELEX procedure and
presented an 11-nt conserved sequence, they displayed different mechanisms to inhibit NS5B.
The 27v aptamer competed with RNA template and inhibited both initiation and elongation
of RNA synthesis, while 127v competed poorly and just inhibited initiation. Also, 27v was able
to inhibit RNA synthesis and HCV particles production on Huh7 cells [83, 84]. The RNA
aptamers r10/43 and r10/47 were isolated against NSB5 of HVC subtype 3a and resulted in the
inhibition of polymerase activity with an estimated KD = 1.4 and 6.0 nM, respectively [85].
In a different approach, chemically modified RNA aptamers (2′-hydroxyl or 2′-fluoropyrimi‐
dine) were isolated against NS5B. The 2′-hydroxyl aptamer inhibited HCV replication on
human liver cells without producing off-target effects or generation of escape mutants. The 2′-
fluoropyrimidine aptamer showed increased affinity to NS5B and efficient inhibition of HCV
replication in cultured cells. This last aptamer was further conjugated with cholesterol or
galactose-polyethylene glycol ligand to increase its availability and specificity for the liver
inhibiting replication of HCV genotype 1b and 2a [86].
Two other RNA aptamers targeting NS5A (NS5A-4 and NS5A-5) reduced the levels of
intracellular infectious virions and viral RNAs by 3-fold and 1-fold, respectively, affecting
virus assembly and release through prevention of the NS5A–core protein interaction. These
NS5A aptamers were specific to HCV without affecting HBV replication and produced
cytotoxicity in human hepatocytes [87].
NS2 contains a transmembrane segment in the N-terminal and a cytoplasmic region in the
C-terminal domain. Although NS2 is essential for HCV RNA replication, its role in HCV’s
life  cycle  is  still  unknown.  Aptamers  NS2-2  and  NS2-3  were  isolated  against  NS2  and
demonstrated  reduced  infectious  virus  production  without  in  vitro  cytotoxicity.  These
aptamers  were  specific  to  HCV  and  did  not  trigger  innate  immunity  responses.  NS2-2
aptamer produces its antiviral effects through binding the NS2 N-terminus thus disrupt‐
ing NS2–NS5 interaction [88].
E2 is an enveloped glycoprotein implicated on initial steps of viral infection by the direct
interaction with CD81. Through cell surface SELEX (CS-SELEX), specific DNA aptamers were
isolated against E2 expressed on CT26 cells. Aptamer ZE2 showed the highest affinity and
specificity to E2 and was able to detect HCV particles and block HCV infection on human
cultured hepatocytes by CD81 binding inhibition [89]. A similar inhibition mechanism was
observed on the DNA aptamer E1E2-6, which inhibited viral infection by blocking host cell
binding [90]. A new system developed to quantify immobilized infectious HCV particles in
microplates (so-called enzyme linked apto-sorbent assay or ELASA) used aptamers against E2
instead of antibodies and resulted in an effective and easy-to-use tool to quantify infectious
units of HCV and to monitor anti-HCV drug efficacies [91].
3. Aptamer structures
Nucleic acid aptamers have a diverse range of secondary structures such as stems, loops,
symmetric or asymmetric internal loops, bulge, single-base bulges and junctions. Aptamer
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internal loops and bulges generally present different conformations in solution and adopt
defined secondary and tertiary structures on ligand–aptamer complex [92]. This effect was
observed on aptamer Sc5-c3 selected against HPV-16 VLPs. Sc5-c3 showed a hairpin structure
with an internal loop, where the main loop (ML) presented two different structures in the
absence of a target (Table 2). Sc5-c3 transition structure was demonstrated by ribonuclease
mapping. Further experiments using Sc5-c3 mutants generated both stable stem and stable
loop conformations, demonstrating that the loop structure binds better to the VLPs [58]. Thus,
as observed in several aptamers, the binding region remains as a flexible single strand as bulges
or loops stabilize conformation arrangements in the presence of a target, producing a very
specific binding.
Although bulges and loops are quite common target-binding motifs in aptamer RNAs, they
are not the only structures present in aptamer–target complexes. Pseudoknots and G-quad‐
ruplexes have also been reported as functional components of aptamers [93]. For example,
some of the aptamers isolated against HIV integrase (93 del and 112 del) presented a G-rich
nucleic acid sequence that was stabilized in the presence of K+ as G-tetrad, increasing their
inhibitory effect [25]. Later reports showed that 93 del adopts an unusually stable dimeric
quadruplex structure [94].
The binding properties of an aptamer are dictated by its sequence and subsequent folding into
secondary and tertiary structures. Recently, functional RNA structures were classified as
critical, connecting, neutral and forbidden structures regarding their particular roles within a
structure [95]. This classification is also applicable to nucleic acid aptamers and is an important
clue to design novel and functional variants for viral detection or therapy.
4. Challenges for aptamer technology
According to their molecular characteristics, RNA or DNA aptamers have some limitations in
their use in animal models and humans. They have limited stability in biological fluids and
are readily degraded by nucleases, unmodified aptamers in the bloodstream possess a half-
life time of less than two minutes. However, many post-SELEX modifications have been
developed to avoid nuclease attack and improve stability in biological fluids. Some modifica‐
tion examples include nucleotide substitutions by 2′-modified variants such as 2′-fluoro (2′-
F), 2′-amino (2′-NH2) or 2′-O-alkyl. Because the most abundant nucleases in biological fluids
are specific to pyrimidines, substitutions in pyrimidine positions appear to be sufficient to
prevent degradation. Another method to stabilize RNA aptamers is the substitution of D-
ribose by L-ribose. As a first step, the aptamers bind the mirror image of the target molecule
to obtain a D-aptamer, then the selected aptamer sequence is synthesized in L-conformation.
As a result of molecular symmetry, the L-ribose–containing aptamer can bind to the target
molecule avoiding degradation by D-ribose–specific nucleases. Moreover, to efficiently
overcome binding issues produced by the introduction of modified nucleotides on the aptamer
sequence, the SELEX procedure can be carried out in the presence of modified libraries.
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Therapeutic aptamers selected against intracellular or nuclear proteins represent bigger
challenges as they need to go across physiological barriers (i.e. cell membrane) before they
reach their targets. DNA and RNA aptamers are characterized by rapid renal clearance leading
to short half-lives in the bloodstream. To address this issue, aptamers can be conjugated to
synthetic polymers such as polyethylene glycol (PEG) to increase their in vivo half-life and
pharmacodynamics [96]. Additionally, PEG-conjugated aptamers show higher cellular uptake
than the unconjugated form [96]. Alternatively, delivery systems such as viral and nonviral
vectors may have improved aptamer cell uptake and nuclear distribution [97]. Vectors or
aptamers alone can be delivered either ex vivo or in vivo. In vivo approaches include intravenous
injection or local implantation and ex vivo refer to the removal of cells followed by in vitro
genetic manipulation and the reintroduction of modified cells. These therapies are still under
evaluation and further studies are necessary to demonstrate their clinical safety. Aptamers
against extracellular or surface viral targets have obvious advantages over aptamers targeting
viral proteins intracellularly expressed, as they can reach exposed areas of infection, such as
the respiratory tract or reproductive organs. This availability makes it possible to develop new
antiviral drugs administrated by noninvasive methods, such as aerosols in case of respiratory
tract infection or topical creams/lotions in case of reproductive organ infections. Many
aptamers are undergoing clinical trials, some of them administrated by noninvasive methods
but, so far, no antiviral aptamer has been approved for human use [18, 98].
5. Conclusion
In the last few years, aptamers have become successful tools for specific viral diagnosis and
genotyping, resulting in the development of many methods based on aptamer–target detection
with very high sensibility and accuracy. On the other hand, aptamer’s role as an antiviral drug
has demonstrated the inhibition of viral infection through in vitro assays and in vivo experi‐
ments using cell lines or animal models. Nevertheless, most aptamers failed to produce results
in clinical trials mostly due to nuclease-associated degradation. Therefore, further develop‐
ment of aptamer’s stability in biofluids and improved pharmacodynamics and delivery
methods are required to overcome clinical issues that would allow its successful therapeutic
application.
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